Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  therapeutic allogeneic lymphocytes
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 60 for your search:
Start Over
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NK_MM_01, NCT01040026
Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: STP-LYM-01-V01, NCT01138579
Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 54
Sponsor: Other
Protocol IDs: BELEHAPLO-1412001, NCT01220544
Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 60
Sponsor: NCI, Other
Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
IL-21-Expanded NK Cells for Induction of Acute Myeloid Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 59
Sponsor: Other
Protocol IDs: 2012-0079, NCI-2014-00883, 8009, NCT01787474
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 17 and over
Sponsor: Other
Protocol IDs: AMC 2012-0478, NCT01795378
Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: 2012-0819, RP110553-P3), NCI-2013-00993, NCT01823198
Infusion of Depleted T Cells Following Transplant in Adults With Acute Leukaemia (ICAT)
Phase: Phase II, Phase I
Type: Supportive care
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UCL/11/0519, 2013-000872-14, MR/K007491/1, NCT01827579
NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 65
Sponsor: Other
Protocol IDs: 2012-0708, NCI-2013-02183, RP110553 05-07-04832, P01 - 5P01, NCT01904136
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 26
Sponsor: Other
Protocol IDs: PLAT-02, NCT02028455
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UKER-BLZ-PH1, NCT02007811
Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: HNJ-NKAES-2012, 2012-000054-63, NCT01944982
Safety and Efficacy Trial for Alpha-Beta Depleted T-Cell Infusions Post Haplo Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 to 65
Sponsor: Other
Protocol IDs: UAB 1397, NCT02193880
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Supportive care
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: CD45RA_NEG_DLI_2014FRCPHOI, NCT02337595
Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 6 months to 80 years
Sponsor: Other
Protocol IDs: DSRB 2014/00452, CTC1400413 (NUH), CTC1400412 (KKWCH), NCT02409576
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 1 to 80
Sponsor: Other
Protocol IDs: 2014-0150, NCT02423915
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: NHLBI
Protocol IDs: CDR0000066610, NHLBI-97-H-0196, NCT00003553
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000271936, FRE-FNCLCC-GETUG-11/0105, EU-20234, NCT00056095
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: 040055, 04-C-0055, NCI-04-C-0055, NCT00077480, NCT00074490
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, P30CA015704, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 271296-HMO-CTIL, NCT00149006
Start Over